AI assistant
Sending…
TriSalus Life Sciences, Inc. — Director's Dealing 2025
May 21, 2025
33473_dirs_2025-05-21_4b438e6d-e8d3-4028-be1b-33e5077e0667.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TriSalus Life Sciences, Inc. (TLSI)
CIK: 0001826667
Period of Report: 2025-05-19
Reporting Person: Marshak Richard (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-19 | Common Stock | A | 21428 | $5.18 | Acquired | 75698 | Direct |
| 2025-05-19 | Common Stock | S | 6597 | $5.18 | Disposed | 69101 | Direct |
Footnotes
F1: The granted RSUs vest immediately.
F2: The sale of the shares was to cover the tax liability associated with the granted RSUs.
More from TriSalus Life Sciences, Inc.
Regulatory Filings
2026
May 14
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Regulatory Filings
2026
Apr 29
Regulatory Filings
2026
Apr 7
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20